Source: International Congress 2018 – Experimental research in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
X. Sun (Amsterdam, Netherlands), E. Peters (Amsterdam, Netherlands), I. Schalij (Amsterdam, Netherlands), S. Andersen (Aarhus, Denmark), D. Da Silva Goncalves Bos (Amsterdam, Netherlands), A. Vonk-Noordegraaf (Amsterdam, Netherlands), F. S De Man (Amsterdam, Netherlands), W. Van Der Laarse (Amsterdam, Netherlands), H. Bogaard (Amsterdam, Netherlands). The effect of Monoamine oxidase A inhibition on experimentally induced pulmonary arterial hypertension. 3072

Member's Comments

No comment yet.

Related content which might interest you: Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 276 Year: 2009 Localisation of NADPH oxidases and their role in hypoxia induced pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 804s Year: 2006 Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Treatment effects of Rho-kinase (Rock) inhibition vs. phosphodiesterase-5 (PDE5) inhibition on cardiac function and metabolism in monocrotaline induced pulmonary arterial hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 547s Year: 2006 Copper restriction prevents and reverses angioproliferation in experimentally induced pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009 Effects of a novel azaindole-based Rho-kinase inhibitor on hemodynamics and pulmonary vascular remodelling in experimental pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 The effect of 6-mercaptopurine treatment on experimentally induced pulmonary arterial hypertension Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition Source: Eur Respir J 2013; 42: 869-870 Year: 2013 Targeting of mitochondrial superoxide in chronic hypoxia-induced pulmonary hypertension Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Reversal of pulmonary hypertension in a sugen/hypoxic rat model using an ASK1 inhibitor Source: International Congress 2017 – New perspectives from experimental models of pulmonary hypertension Year: 2017 Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension Source: Eur Respir J, 56 (5) 2000522; 10.1183/13993003.00522-2020 Year: 2020 Effect of mitochondrial inhibitors and uncouplers on hypoxic pulmonary vasoconstriction Source: Eur Respir J 2002; 20: Suppl. 38, 4s Year: 2002 Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016 Year: 2017 Attenuated expression and activity of dimethylarginine dimethylaminohydrolase may play a key role in monocrotaline-induced pulmonary hypertension by accumulation of endogenous NOS inhibitors in rats Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 The modulatory effects of Nrf2 activators in a pulmonary arterial hypertension model Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Inhibition of Monoamine Oxidase A in pulmonary artery banding-induced right heart failure Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 NOX1 derived generation of reactive oxygen species in monocrotaline-induced pulmonary arterial hypertension of rats Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Comparison of acute hemodynamic effects of three different phosphodiesterase inhibitors in patients with pulmonary arterial hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 705s Year: 2004